Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study.

Vasilios TzilasArgyris TzouvelekisEvangelos BourosTheodoros KarampitsakosMaria NtassiouEleni AvdoulaAthina TrachalakiKaterina AntoniouGanesh RaghuDemosthenes Bouros

Published in: ERJ open research (2020)

In patients with f-HP receiving antifibrotics there is a statistically significant annual decline in FVC % pred and D LCO % pred over a period of 3 years. Prospective randomised trials exceeding 1 year are warranted to determine the long-term efficacy of antifibrotics.

Keyphrases

clinical trial
open label
systemic sclerosis
double blind
study protocol
interstitial lung disease
idiopathic pulmonary fibrosis
drug induced
placebo controlled
randomized controlled trial
rheumatoid arthritis